Innovations in stroke clinical trial design

Karen L. Furie, Michael K. Parides

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The pace of development of new drugs and devices for the treatment of stroke is dependent upon the rate that promising compounds can be tested in humans. While this final stage of drug development is the product of years of preclinical work, it is a critical step not only because these trials are extremely expensive and take many years to complete but also because poorly designed clinical trials can derail a promising therapy or promote an ineffective one. Historically, the stroke field has suffered from a poor track record in drug development. The only approved therapy for acute stroke is intravenous tPA (N Engl J Med 333:1581-87). Stroke preventive therapies include antithrombotic agents and statins (Eur Heart J. 2008;29:1082-3; BMJ. 2002;324:71-86; N Engl J Med. 2006;355:549-59). There are no proven therapies for stroke recovery. There are numerous obstacles inherent to developing therapies for stroke, such as the need to deliver drug to the affected blood vessels and injured brain tissue, the narrow window for intervention, and the heterogeneity of the patient population.

Original languageEnglish (US)
Title of host publicationTranslational Stroke Research
Subtitle of host publicationFrom Target Selection to Clinical Trials
PublisherSpringer New York
Pages911-916
Number of pages6
ISBN (Electronic)9781441995308
ISBN (Print)9781441995292
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Fingerprint

Stroke
Clinical Trials
Pharmaceutical Preparations
Therapeutics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Fibrinolytic Agents
Population Characteristics
Blood Vessels
Equipment and Supplies
Brain

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

Furie, K. L., & Parides, M. K. (2012). Innovations in stroke clinical trial design. In Translational Stroke Research: From Target Selection to Clinical Trials (pp. 911-916). Springer New York. https://doi.org/10.1007/978-1-4419-9530-8_43

Innovations in stroke clinical trial design. / Furie, Karen L.; Parides, Michael K.

Translational Stroke Research: From Target Selection to Clinical Trials. Springer New York, 2012. p. 911-916.

Research output: Chapter in Book/Report/Conference proceedingChapter

Furie, KL & Parides, MK 2012, Innovations in stroke clinical trial design. in Translational Stroke Research: From Target Selection to Clinical Trials. Springer New York, pp. 911-916. https://doi.org/10.1007/978-1-4419-9530-8_43
Furie KL, Parides MK. Innovations in stroke clinical trial design. In Translational Stroke Research: From Target Selection to Clinical Trials. Springer New York. 2012. p. 911-916 https://doi.org/10.1007/978-1-4419-9530-8_43
Furie, Karen L. ; Parides, Michael K. / Innovations in stroke clinical trial design. Translational Stroke Research: From Target Selection to Clinical Trials. Springer New York, 2012. pp. 911-916
@inbook{dcf761d952ac495abb590c47af378c7c,
title = "Innovations in stroke clinical trial design",
abstract = "The pace of development of new drugs and devices for the treatment of stroke is dependent upon the rate that promising compounds can be tested in humans. While this final stage of drug development is the product of years of preclinical work, it is a critical step not only because these trials are extremely expensive and take many years to complete but also because poorly designed clinical trials can derail a promising therapy or promote an ineffective one. Historically, the stroke field has suffered from a poor track record in drug development. The only approved therapy for acute stroke is intravenous tPA (N Engl J Med 333:1581-87). Stroke preventive therapies include antithrombotic agents and statins (Eur Heart J. 2008;29:1082-3; BMJ. 2002;324:71-86; N Engl J Med. 2006;355:549-59). There are no proven therapies for stroke recovery. There are numerous obstacles inherent to developing therapies for stroke, such as the need to deliver drug to the affected blood vessels and injured brain tissue, the narrow window for intervention, and the heterogeneity of the patient population.",
author = "Furie, {Karen L.} and Parides, {Michael K.}",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/978-1-4419-9530-8_43",
language = "English (US)",
isbn = "9781441995292",
pages = "911--916",
booktitle = "Translational Stroke Research",
publisher = "Springer New York",

}

TY - CHAP

T1 - Innovations in stroke clinical trial design

AU - Furie, Karen L.

AU - Parides, Michael K.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - The pace of development of new drugs and devices for the treatment of stroke is dependent upon the rate that promising compounds can be tested in humans. While this final stage of drug development is the product of years of preclinical work, it is a critical step not only because these trials are extremely expensive and take many years to complete but also because poorly designed clinical trials can derail a promising therapy or promote an ineffective one. Historically, the stroke field has suffered from a poor track record in drug development. The only approved therapy for acute stroke is intravenous tPA (N Engl J Med 333:1581-87). Stroke preventive therapies include antithrombotic agents and statins (Eur Heart J. 2008;29:1082-3; BMJ. 2002;324:71-86; N Engl J Med. 2006;355:549-59). There are no proven therapies for stroke recovery. There are numerous obstacles inherent to developing therapies for stroke, such as the need to deliver drug to the affected blood vessels and injured brain tissue, the narrow window for intervention, and the heterogeneity of the patient population.

AB - The pace of development of new drugs and devices for the treatment of stroke is dependent upon the rate that promising compounds can be tested in humans. While this final stage of drug development is the product of years of preclinical work, it is a critical step not only because these trials are extremely expensive and take many years to complete but also because poorly designed clinical trials can derail a promising therapy or promote an ineffective one. Historically, the stroke field has suffered from a poor track record in drug development. The only approved therapy for acute stroke is intravenous tPA (N Engl J Med 333:1581-87). Stroke preventive therapies include antithrombotic agents and statins (Eur Heart J. 2008;29:1082-3; BMJ. 2002;324:71-86; N Engl J Med. 2006;355:549-59). There are no proven therapies for stroke recovery. There are numerous obstacles inherent to developing therapies for stroke, such as the need to deliver drug to the affected blood vessels and injured brain tissue, the narrow window for intervention, and the heterogeneity of the patient population.

UR - http://www.scopus.com/inward/record.url?scp=85027337963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027337963&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-9530-8_43

DO - 10.1007/978-1-4419-9530-8_43

M3 - Chapter

SN - 9781441995292

SP - 911

EP - 916

BT - Translational Stroke Research

PB - Springer New York

ER -